Acute myeloid leukemia developing secondary to prior cytotoxic chemotherapy (s-AML) encompasses a range of distinct entities. We report two cases of s-AML with inv(16)(p13q22) who had prior exposure to paclitaxel. Additionally, two previously reported cases of s-AML with inv(16) had prior paclitaxel exposure raising the possibility that the taxanes may predispose to this specific syndrome of s-AML. One of our patients received escalated-dose ara-C chemotherapy, achieving a complete remission (12+ months). We therefore examined the prognosis of previously reported cases of s-AML with inv(16) and analyzed the influence of escalated-dose ara-C (у400 mg/m 2 /day). A total of 25 evaluable cases were identified, with 96% attaining CR independent of ara-C dose. The estimated median remission duration was 40 months and the median survival has not been reached (actuarial 5-year survival 52 ± 18%). Although not achieving statistical significance, patients treated with escalated dose ara-C (n = 15) had longer remission duration and overall survival than those treated with standard dose ara-C (n = 10) (P = 0.063 and 0.20, respectively). In univariate analysis, younger age, male gender, and the presence of additional cytogenetic abnormalities were associated with a tendency towards adverse outcomes (P Ͻ 0.1). Age and gender were equally distributed between ara-C dose cohorts, but more patients treated with standard-dose ara-C had additional cytogenetic abnormalities (P = 0.048). Within the limitations of this retrospective study, this analysis suggests that, similar to de novo AML with inv(16), secondary cases may also potentially benefit from treatment with escalated-dose ara-C. This is consistent with the premise that the underlying molecular defect, rather than the presence of prior cytotoxic drug exposure, may be the most important determinant of disease behavior and chemotherapy responsiveness in AML.
Introduction
Since the initial descriptions of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) following cytotoxic chemotherapy, 1, 2 there have been substantial improvements in our understanding of the clinical heterogeneity, and varied pathophysiologic processes resulting in this spectrum of disorders. 3 The dominant clinical syndrome represented in these early reports was of older patients usually many years after alkylating agent and/or radiation therapy, presenting with a recognised MDS with partial deletions, or monosomy, of chromosome 5, and/or 7, which frequently progressed to frank AML and was poorly responsive to conventional antileukemic therapy. [1] [2] [3] Subsequently, the strong association between abnormalities of chromosome 11q23 at the site of the MLL gene, 4 and prior exposure to the epipodophyllotoxins was clearly delineated. 3, 5 Throughout this period, with some notable exceptions, 6, 7 it was generally held that the prognostically favorable balanced translocations, particularly inv(16), were not within the spectrum of chromosomal abnormalities caused by prior cytotoxic therapies. 8, 9 However, in the last 5 years there has been an increasing recognition of the occurrence, albeit uncommon, of inv (16) in patients with secondary AML (s-AML). 3, [10] [11] [12] [13] [14] The previously published cases of this phenomenon together with six new cases from Copenhagen and Chicago were recently reviewed by Dissing et al, 13 where they suggest that exposure to topoisomerase-ll targeting drugs, particularly the anthracyclines, may specifically predispose to such a chromosomal abnormality. 13 Notably, two of the reviewed cases had received prior therapy including paclitaxel. We now present two additional cases of women with s-AML M4Eo and inv (16) following prior combination chemotherapy including the micro-tubule targeting agent paclitaxel, raising the possibility that the taxanes may also predispose to this significant late complication. We also review the long-term outcome of previously reported cases of s-AML with inv (16) to clarify the prognostic significance of this syndrome and examine the influence of ara-C dose-intensification in this group, given emerging data on the favorable impact of such therapy in patients with de novo AML and inv(16).
15,16

Methods
Previously published cases of s-AML with inv(16) were identified by a combination of Medline searching from 1970 to 1998, manual searching of known reviews of s-AML or inv (16) , and proceedings of relevant conferences. In addition, one previously unpublished case was identified from the computerised database of the Leukemia Department of the MD Anderson Cancer Center (Houston, TX, USA). To be considered for inclusion, cases must have received prior cytotoxic therapy (those with previous radiation therapy only were excluded) and have a documented clonal cytogenetic abnormality involving the standard breakpoints: inv(16)(p13q22). For all reported cases, the following data were extracted: age at onset of s-AML, gender, primary tumor type, interval between first exposure to cytotoxic drugs and onset s-AML (latency period), the presence of additional cytogenetic abnormalities, whether anti-leukemic treatment was administered, the dose intensity of ara-C (high vs standard), the attainment of CR, CR duration, and overall survival. For the purposes of this analysis, 'high'-dose ara-C was defined as any treatment regimen administering у400 mg/m 2 /day based on the doseintensity data from the CALGB, 16 regardless of total treatment duration. Patients were classified as having received high-dose ara-C whether this was administered as induction therapy, or following the attainment of CR.
Numeric data are presented as the median and range unless stated otherwise. Possible associations between categorical and continuous variables were tested using the MannWhitney U test and between pairs of categorical variables using Fisher's exact test or the 2 test, as appropriate. Survival data were analyzed using the method of Kaplan and Meier and compared using the log-rank test, with proportions presented ± the standard error (s.e.). Given the published data in de novo AML with inv(16), 15, 16 we approached this study with the a priori hypothesis that escalated-dose ara-C would result in superior outcome. Thus, P values for the influence of ara-C dose are one-sided. As all other comparisons were exploratory in nature, two-sided P values are applied.
Case reports
Patient 1
A previously well 57-year-old woman was diagnosed with stage IIIC ovarian adenocarcinoma. Following optimal surgical debulking she received six cycles of cyclophosphamide and cisplatin (total cumulative doses 8400 mg and 840 mg, respectively), attaining a complete biochemical and radiologic response with a negative second-look laparotomy. However, 7 months after completing chemotherapy, she was found to have progressive disease and received six cycles of carboplatin and paclitaxel (total cumulative doses of 3600 mg and 1800 mg, respectively), again attaining a complete biochemical and radiologic remission.
Twenty-two months after her initial chemotherapy and 10 months after her first exposure to paclitaxel, she was investigated for symptomatic anemia and thrombocytopenia; hemoglobin 54 g/l, total leukocyte count 30.6 × 10 9 /l (blasts 20.4, monocytes 6.14 and eosinophils 0.37 × 10 9 /l) and platelets 11 × 10 9 /l. Her marrow was hypercellular with 57% myeloid blasts (some containing Auer rods), abnormal eosinophilic precursors, and 12% monocytes consistent with AML M4Eo. In addition, there was morphologic trilineage dysplasia. Myeloperoxidase and esterase staining were confirmatory. Cytogenetic studies revealed inv(16)(p13q22) in 20 of 20 metaphases without additional abnormalities. The patient also had significant elevations of plasma levels of lactate dehydrogenase and lysozyme. CT scanning of the abdomen showed no evidence of recurrent ovarian cancer, and her serum level of CA-125 was normal.
She received induction therapy with a 7 day infusion of ara-C 100 mg/m 2 /day, idarubicin 12 mg/m 2 /day × 3, and etoposide 75 mg/m 2 /day × 7, attaining morphologic and cytogenetic complete remission on day 28. Due to mild but persisting headaches cerebrospinal fluid (CSF) examination was performed which confirmed leptomeningeal leukemic infiltration, although cerebral computerised tomographic scanning was normal. Consolidation therapy comprised two cycles of ara-C (3 g/m 2 loading dose followed by continuous infusion of 1.5 g/m 2 /day for 3 days), with repeated intrathecal therapy. When last reviewed 13 months post-diagnosis, she remained in ongoing complete remission of her AML with negative CSF cytology, but had evidence of progressive ovarian cancer with a rising serum level of CA-125.
Patient 2
A 53-year-old woman without prior illness was diagnosed with metastatic neuroendocrine carcinoma of the ovary. Her disease was poorly responsive to multiple chemotherapy regimens including the following agents: cyclophosphomide (total dose 2400 mg), mitoxantrone (38 mg), carboplatin (750 mg), etoposide (350 mg), epirubicin (50 mg) and paclitaxel (450 mg). Palliative radiation therapy was also administered to painful bone lesions. Then, 17 months after her initial chemotherapy and 8 months after her first exposure to paclitaxel she was noted to have abnormal blood counts (hemoglobin 135 g/l, total leukocyte count 8.3 × 10 9 /l (blasts 3.7 and eosinophils 0.2 × 10 9 /l), and platelets of 9 × 10 9 /l) and underwent a bone marrow examination. The marrow was hypercellular with 61% myeloid blasts (some containing Auer rods), abnormal eosinophilic precursors, and 7% monocytes consistent with AML M4Eo. Moderate morphologic dysplasia was evident, predominantly in the erythroid series. Cytogenetic studies showed isolated inv(16)(p13q22) in all 20 metaphases examined. In view of her progressive metastatic ovarian cancer, she declined specific therapy for her s-AML and died 10 weeks later.
Results
Previously reported cases of s-AML with inv(16)
Including the two cases described above, and one previously unreported case from the database of the MD Anderson Cancer Center, a total of 36 cases of s-AML with inv(16) were identified. Of these, 11 were excluded from analysis for the following reasons: insufficient details available in two, 17, 18 no anti-leukemic treatment administered in three (including current case 2), 19, 20 prior radiation therapy only in three, 13, 21, 22 aberrant breakpoints in one 23 unacknowledged multiple publication in one, 19, 24 and finally, one case included in an earlier review (patient number 5 from Quesnel et al 12 ) could not be verified from the primary reference cited. 25 Thus, 25 cases with treatment and follow-up data were available for analysis 6, [12] [13] [14] 19, [26] [27] [28] [29] (Table 1) . Follow-up information on the six cases from the MD Anderson Cancer Centre was updated to May 1999. For the end-point of remission duration, the median follow-up of patients in ongoing remission is 17 months (range 4-134 months), and for overall survival the median follow-up of surviving patients is 16.5 months (range 4-135 months). Including the two present cases, four of these patients had previous exposure to paclitaxel.
Influence of ara-C dose on long-term outcome
Of the 25 evaluable cases of s-AML with inv(16), 24 achieved CR with induction therapy (96%; 95% confidence intervals 80-100%). For the entire cohort, the overall median remission duration is 40 months, and the overall median survival has not yet been reached (actuarial 10-year survival 52 ± 18%). To examine the influence of received ara-C dose on long-term outcome, patients were classified according to whether they had received standard-, or escalated (у400 mg/m 2 /day) dose ara-C during either induction or consolidation treatment (Table 2) . Fifteen patients received escalated-dose ara-C with 14 (93%) attaining CR, while 10 patients received standarddose ara-C with all 10 (100%) attaining CR. Of the patients attaining CR, 44 ± 18% of those treated with standard-dose ara-C are anticipated to remain in ongoing remission at 2 years, compared with 76 ± 12% of those treated with highdose ( Figure 1a ; overall one-sided P = 0.063). In the high-dose ara-C group, there have been no relapses beyond 40 months and three patients remain in ongoing first CR at 90, 110 and 134 months. Overall survival similarly favored patients treated with high-dose ara-C (Figure 1b ; overall one-sided P = 0.20); 84 ± 11% vs 49 ± 23% at 3 years. At least in part due to the small number of patients analyzed, neither of these differences achieved statistical significance.
To further explore these consistent trends in outcome favoring patients treated with high-dose ara-C, the distribution of other possible prognostic factors was examined (Table 2) . Patients treated with high-dose ara-C were of similar age, and gender distribution as those treated with standard-dose ara-C, however, they were less likely to have additional cytogenetic abnormalities (40% compared with 80%; P = 0.048), and had a longer latency period between their prior chemotherapy and the diagnosis of AML (median 36 vs 16 months; P = 0.013).
The prognostic influence of these parameters was then examined in the whole cohort of 25 patients (Table 3 ). There were trends toward inferior remission duration among younger patients (below the median of 47 years; P = 0.07), males (P = 0.09), and for those with additional cytogenetic abnormalities (P = 0.06). However, for the end-point of overall survival, the impact of most of these factors was diminished, with only male gender maintaining an influence on outcome (P = 0.03). There were too few patients to allow formal multivariate analysis of the independent role of ara-C dose intensity relative to these factors.
Discussion
The two new cases of s-AML with inv (16) described in this report demonstrate a number of the features of this syndrome highlighted in recent reviews; 12, 13 an abrupt clinical onset of AML with a relative short latency from their prior chemotherapy, and the absence of a recognised myelodysplastic
Figure 1
Long-term outcome of secondary AML with inv(16) according to ara-C dose. (a) Remission duration; only those patients attaining CR are evaluable, thus one of the 15 patients treated with high-dose ara-C who did not attain CR is excluded. (b) Overall survival; one of the patients treated with high-dose ara-C did not have survival data available, and is excluded from the analysis. P values are one-sided by log-rank test. phase. However, in contrast to the recent emphasis on the role of topoisomerase II-targeting agents in the pathogenesis of s-AML with inv(16), 13, 30 a shared feature of these two cases was their prior treatment with paclitaxel, although our second patient had also received small doses of topoisomerase II active agents. Notably, two of the cases reported by Dissing et al 13 had also been treated with paclitaxel. The presence of clear morphologic dysplasia in both of our cases suggests their disease was therapy-related, as such features are extremely uncommon in cases of de novo AML M4Eo with inv(16). 31, 32 Furthermore, the clear female predominance among patients with s-AML and inv (16) , in contrast with de novo cases, [31] [32] [33] also supports a causative role for the preceding exposure to the classes of cytotoxic drugs preferentially used in the current management of breast and ovarian cancer: the taxanes and anthracyclines.
Historically, while patients receiving many types of chemotherapy for ovarian cancer, 34 and more specifically platinumbased chemotherapy 35, 36 are recognised to have moderately increased risk of subsequent AML, such cases have generally been of more insidious onset, occurred later following treatment, and have been associated with the gross, unbalanced chromosomal changes characteristic of alkylating-agent related s-AML.
3 While we have previously described transient morphologic abnormalities in neutrophils of patients treated with the taxanes, 37 possibly related to its known actions on mitotic micro-tubules, there are no previous data suggesting an association with more prolonged, or irreversible dysplastic changes, or s-AML, although paclitaxel is established to have mutagenic properties in vitro. 38 While these isolated observations do not establish a causal link between paclitaxel exposure and subsequent s-AML with inv(16), they do underline the need for careful ongoing surveillance of patients treated with taxanes, and suggest that analysis of late toxicities occurring in patients enrolled on the many recent large randomised studies is required.
The favorable early outcome of our first case prompted an examination of the long-term prognosis of previously reported cases and an analysis of the possible role of dose-intensified ara-C which is of clear benefit in patients with de novo AML and inv (16) . 15, 16 While such an analysis is unavoidably ham-pered by the small number of evaluable patients and possible publication biases, a number of suggestive features emerged. In contrast to the poor prognosis of s-AML generally, 3,39 such patients with inv(16) appear to share the relatively favorable outlook of patients with de novo inv(16), as they had an extremely high CR rate regardless of induction treatment (96%) and a good probability of long-term disease control and possible cure; 50% of patients remain in ongoing first CR beyond 40 months with no late relapses observed. This excellent long-term outlook certainly justifies consideration of 'optimal' anti-leukemic therapy in patients with s-AML and inv (16) even in the setting of prior malignancy or older age. Furthermore, the finding of leptomeningeal infiltration in case 1 suggests that these patients also share the increased risk of central nervous system disease identified for patients with de novo disease. 40 In contrast to the lack of consistent adverse prognostic influence of additional cytogenetic abnormalities among patients with de novo AML and inv (16) , 33, 41, 42 the current analysis suggests that the presence of additional cytogenetic abnormalities may be associated with an inferior outcome among patients with s-AML and inv (16) . While there were too few patients for multivariate analysis, it is possible that the disproportionate frequency of additional cytogenetic abnormalities also contributed to the apparent inferior outcome of males and younger patients, as among these sub-groups the frequency of additional cytogenetic changes were 89% and 67%, respectively. If the presence of additional cytogenetic abnormalities is truly associated with an inferior outcome among patients with s-AML and inv (16) , it is difficult to explain why this would not also be the case in patients with de novo disease, as the frequency and spectrum of these associated abnormalities did not differ from that previously reported. 33, 41 Ultimately, this question can only be adequately addressed through the analysis of larger numbers of patients.
Within the limitations of the small number of evaluable patients, our remission duration and survival data (Figure 1 ) are consistent with a similar improvement in outcome with escalated doses of ara-C seen in patients with de novo inv (16) . 15, 16 Given the variability in other baseline demographic and prognostic variables between groups (particularly the frequency of additional cytogenetic abnormalities), and the uncertain biases leading to publication, this conclusion cannot be regarded as definitive. However, it is supported by the finding of increased sensitivity of AML cells with inv (16) to ara-C in vitro compared with other cytogenetic groups, attributable to the accumulation of higher concentrations of the active triphosphate ara-CTP, and the incorporation of significantly more drug into leukemic cellular DNA. 43 Although a smaller number of patients with inv(16) were studied, an earlier analysis of patients from the MD Anderson Cancer Center had not shown any such differences in steady-state intracellular ara-CTP concentrations during infusional delivery of ara-C. 15 The suggestion of possible superiority of escalated-dose ara-C in patients with s-AML and inv (16) is consistent with the historically controlled and randomized data in patients with de novo disease, and supported by preclinical predictions. Given the rarity of such patients, and the fact that no prospective study could ever be implemented to address this question, it would be reasonable to consider the routine use of escalated-dose ara-C (at least 400 mg/m 2 /day) in this setting, unless clearly contraindicated. Finally, the similar disease features, drug sensitivity, and long-term outcome between patients with de novo and s-AML with inv (16) suggests that the underlying molecular defects present in the leukemic blasts are a more important determinant of disease behavior and prognosis than the presence or absence of prior cytotoxic chemotherapy. Such a hypothesis may have significant implications for our current approach to the classification and management of patients with the more common chromosomal abnormalities involving 11q23 and chromosomes 5 and 7.
